Meeting
2021 ASCO Annual Meeting
Efficacy of naxitamab in patients with refractory/relapse (R/R) high-risk neuroblastoma (HR-NB) by bone/bone marrow (BM) evaluation, potential sites of residual disease.
Authors
Brian H. Kushner
Memorial Sloan Kettering Cancer Center, New York, NY
Brian H. Kushner , Daniel A. Morgenstern , Karsten Nysom , Melissa K. Bear , Karen Tornøe , Nedjad Losic , Jaume Mora
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT03363373
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 10022)
DOI
10.1200/JCO.2021.39.15_suppl.10022
Abstract #
10022
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Reduction in Curie score in neuroblastoma patients treated with naxitamab.
First Author: Jaume Mora
Poster
2023 ASCO Annual Meeting
Two schedules of vincristine, irinotecan and temozolomide (VIT) for patients with relapsed or refractory Ewing sarcoma: A randomized controlled phase 2 trial.
First Author: Jie Xu
Poster
2023 ASCO Annual Meeting
The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.
First Author: Krish Patel
Poster
2022 ASCO Annual Meeting
Naxitamab and granulocyte macrophage colony stimulating factor (GM-CSF) in combination with irinotecan and temozolomide in patients with high-risk neuroblastoma with primary refractory disease or in first relapse: An international, single-arm, multicenter phase 2 trial.
First Author: Godfrey Chi-Fung Chan